Evidence map›Paper›PMID 22341543›Full record

ReviewClinics in perinatology2012

Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Nicolas F M Porta, Robin H Steinhorn

Open access · greenAbstract readReview
In one paragraph

Review in Clinics in perinatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Review
  3. Implementation of an Inhaled Nitric Oxide Weaning Protocol and Stewardship in a Level 4 NICU to Decrease Inappropriate Use.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Sildenafil Exposure in the Neonatal Intensive Care Unit.American journal of perinatology · 2019
    Article
  10. Reduced oxygen concentration for the resuscitation of infants with congenital diaphragmatic hernia.Journal of perinatology : official journal of the California Perinatal Association · 2018
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Lung Circulation.Comprehensive Physiology · 2016
    Review
  17. Trends in treatment and in-hospital mortality for neonates with congenital diaphragmatic hernia.Journal of perinatology : official journal of the California Perinatal Association · 2015
    Article
  18. Article
  19. Article
  20. Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia.Pediatric allergy, immunology, and pulmonology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicolas F M PortaDepartment of Pediatrics, Children's Memorial Hospital, Northwestern University, Chicago, IL 60614, USA. n-porta@northwestern.edu
Robin H Steinhorn
Northwestern Memorial Hospital · US

Funding

REDOX REGULATION IN THE PERINATAL PULMONARY VASCULATURER01HL054705 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI STEINHORN, ROBIN H. · 2001 to 2013
$4.8M
Phase II Trial of Sildenafil in Newborns with Persistent Pulmonary HyptertensionU01HL102235 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ABMAN, STEVEN HERBERT, CUTTER, GARY R · 2010 to 2010
$1.3M
NHLBI NIH HHS R01 HL054705NHLBI NIH HHS R01HL54705NHLBI NIH HHS U01 HL102235NHLBI NIH HHS U01HL102235
6 · The paper itself

Abstract

The perinatal transition from fetal to extrauterine life requires a dramatic change in the circulatory pattern as the organ of gas exchange switches from the placenta to the lungs. Pulmonary hypertension can occur during early newborn life, and present as early respiratory failure or as a complication of more chronic diseases, such as bronchopulmonary dysplasia. The most effective pharmacotherapeutic strategies for infants with persistent pulmonary hypertension of the newborn are directed at selective reduction of pulmonary vascular resistance. This article discusses currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness.

Indexed as

Intensive Care Units, NeonatalAdministration, InhalationEndothelium-Dependent Relaxing FactorsHumansHypertension, PulmonaryInfant, NewbornNitric OxidePhosphodiesterase InhibitorsPiperazinesPurinesSildenafil CitrateSulfonesVasodilator AgentsEndothelium-Dependent Relaxing FactorsNitric OxidePhosphodiesterase InhibitorsPiperazinesPurinesSildenafil CitrateSulfonesVasodilator Agents

Identifiers

PMID22341543
PMCPMC3562500
OpenAlexW2046204411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.